Press releases
Cessatech’s press releases provide updates on the company’s news and developments.
2025
251113 – Cessatech Q3_2025 Report
251031 – STAQ collaboration for CT001 in the US
250821 – Cessatech Q2-2025 Report
250814 – MAA submitted for CT001 to EMA
250627 – Q&A Cessatech presentation in June
250619 – Executive Management_Martin Juhl
250611 – Registration of directed issue
250528 – Completion of the directed issue
250528 – Launch of directed issue offering
250528 – Top line results Study 0202
250515 – Cessatech Q1-2025 Report
250430 – Last patient Study 0202
250328 – Minutes_Annual General Meeting
250312 – Notice for Annual General Meeting
250228 – Annual Report 2024
250204 – Positive CT001 MDR assessment
2024
241223 – Milestones for coming year (2025)
241113 – Cessatech Q3-2024 Report
241016 – Halfway milestone on Study 0202
240902 – Proveca_Agreement_Q&A
240826 – Proveca_Cessatech partnership
240821 – Cessatech Q2-2024 Report
240812 – Loan Facility Agreement, extended
240802 – Key priorities for the rest of the year
240726 – IncentiveWarrantProgram (WPIII)
240705 – Anders D. Dombernowsky-Toft to join BoD
240705 – Minutes of EGM Cessatech – 5 JULY 2024
240628 – CT001 new data on paediatric pain relief at the PAGE conference in Rome
240620 – EGM notice JUN2024
240603 – CT001 simulated pain in children
240527 – First patient dosed in Safety Study 0202
240515 – Cessatech Q1-2024 Report
240327 – Minutes_Annual General Meeting 2023
240229 – Annual Report 2023
240130 – Result of warrant exercise
240123 – Last day of trading TO2 warrants
240122 – Management and board exercises T02 warrants
240104 – Q&A session from Study 0205
2023
231222 – Topline results of study 0205
231116 – Cessatech Q3_2023 Report
231025 – Update on Study 0202
230921 – Last participant dosed in pivotal trial 0205
230912 – Announcement on EMA agreed PIP for CT002
230824 – Cessatech Q2-2023 Report
230817 – Loan facility agreement to support US launch
230630 – Cessatech – Ventis Pharma US partnership – Q&A
230627 – Ventis Cessatech US Partnership
230531 – Stability data and shelf-life of CT001
230516 – Q1-2023_Q&A session
230512 – Cessatech_Q1-2023 Report
230323 – New Chairman of the Board
230323 – Minutes_AnnualGeneralMeeting_2022
230308 – Notice for Annual General Meeting
230228 – CT_ANNUAL REPORT (including Q4 results) 2022
230228 – Annual Report 2022_Release
230117 – IncentiveWarrantProgram (WPII)
2022
221207 – Registration of issueance of compensation units
221118 – Last day of trading in Cessatech BTUs
221118 – Cessatech_Q3-2022 Report
221114 – Outcome of Cessatech rights issue
221108 – Subscription period ends in Cessatech rights issue
221104 – Extraordinary general meeting minutes
221027 – Subscription period starts in Cessatech rights issue
221020 – Cessatech – Notice to EGM
221020 – Cessatech publishes offering memorandum
221019 – Announcement of Rights issue
220923 – TopLine Results of trial 0206
220905 – First patient dosed trial 0205
220819 – Cessatech_Q2-2022 Report
220630 – Regulatory green light trial0205
220516 – Last patient in trial 0206
220419 – Cessatech_Q1-2022 Report
220317 – AnnualGeneral Meeting 2022_Minutes
220308 – trial 0204 successful topline results
220303 – Annual Report 2021
220302 – Cessatech_AnnualGeneralMeeting_2021_Agenda
220224 – Cessatech_Q4-2021_Report
220222 – Trial 0204 results expected soon
220106 – Changes to the Board of Directors
220104 – Warrant exercise registered
2021
211222 – Cessatech successfully raises approx. DKK 24.3 million through warrant exercise
211214 – Last day of trading_CT warrants of series TO 1
211208 – BoD and CEO exercise their TO 1 warrants
211125 – Exercise period for Warrants TO 1
211119 – Cessatech_Q3-2021 Report
211102 – US patent issuance
210820 – First patient in trial 0206…
210819 – Cessatech_Q2-2021 Report
210629 – NewChairman of the Board
210531 – Last subject dosed trial 0204
210514 – IPO of the year 2020
210419 – Cessatech_Q1-2021 Report
212603 – Minutes_Annual General Meeting 2021
210324 – First subject dosed trial 0204_
210311 – Annual Report Release 2020
210310 – Annual General Meeting 2021
210309 – Best Medical Treatment IPO Nordics Award – CFI.co
210304 – Favourable data from the Registry Safety Study
210211 – Year-end report Q4-2020
2020
201215 – Invitation to listing ceremony
201214 – IncentiveWarrantProgram (WPI)
201127 – Significantly oversubscribed IPO
201110 – The subscription period in the IPO commences
201106 – Approval for listing and publishes prospectus